Med. Oncol.
To be or not to be: whether anti-angiogenic agent combined with immune checkpoint inhibitoris necessary in the treatment of advanced or metastatic renal cell carcinoma.
Sun L, Zhang L, Yu J, Zhou Y, Shi C, Wasan HS, Ruan S, Huang D
Although it's widely known that targeted therapy against angiogenesis and immunotherapy agents showed survival benefit over chemoradiotherapy in advan ...
Read More
Source: PubMed
Eur Urol Focus 2020 Jan 29
The Biology of Tumour Evolution in Renal Cell Carcinoma.
Tippu Z, Au L, Turajlic S
A diverse range of clinical phenotypes are observed in clear-cell renal cell carcinoma (ccRCC) with resultant therapeutic implications. Molecular char ...
Read More
Source: PubMed
Eur J Surg Oncol 2020 Jan 22
Predicting positive surgical margins in partial nephrectomy: A prospective multicentre observational study (the RECORd 2 project).
Schiavina R, Mari A, Bianchi L, Amparore D, Antonelli A, Artibani W, Brunocilla E, Capitanio U, Fiori C, Di Maida F, Gontero P, Larcher A, Li Marzi V, Longo N, Marra G, Montanari E, Porpiglia F, Roscigno M, Simeone C, Siracusano S, Tellini R, Terrone C, Villari D, Ficarra V, Carini M, Minervini A
to evaluate clinical predictors of positive surgical margins (PSMs) in a large multicenter prospective observational study and to develop a clinic nom ...
Read More
Source: PubMed
Clin Nutr 2020 Jan 22
Automated body composition analysis of clinically acquired computed tomography scans using neural networks.
Paris MT, Tandon P, Heyland DK, Furberg H, Premji T, Low G, Mourtzakis M
The quantity and quality of skeletal muscle and adipose tissue is an important prognostic factor for clinical outcomes across several illnesses. Clini ...
Read More
Source: PubMed
Urologe A 2020 Jan 31
[Risk-adapted therapy for metastatic renal cell carcinoma].
Grimm MO, Leucht K, Foller S, Grünwald V
Current pivotal phase 3 studies have permanently changed the first-line treatment landscape in metastatic renal cell carcinoma. These studies showed t ...
Read More
Source: PubMed
